Deep Track Capital
Latest statistics and disclosures from Deep Track Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are JAZZ, INSM, IONS, TVTX, GPCR, and represent 29.24% of Deep Track Capital's stock portfolio.
- Added to shares of these 10 stocks: GH (+$54M), EDIT (+$28M), ANIP (+$28M), AXSM (+$28M), ZURA (+$21M), TVTX (+$19M), PRTA (+$17M), MORF (+$12M), SWTX (+$12M), PLRX (+$11M).
- Started 14 new stock positions in MLTX, CMPS, FGEN, AXSM, TERN, MORF, GH, ZURA, Orchard Therapeutics Plc ads, ZNTL. EDIT, ANIP, INKT, PRTA.
- Reduced shares in these 10 stocks: ISEE (-$158M), KDNY (-$70M), RETA (-$66M), , DICE (-$46M), SGEN (-$44M), IMVT (-$38M), , ARGX (-$37M), PACB (-$27M).
- Sold out of its positions in ACRS, ARGX, BIIB, KDNY, DICE, DCPH, EXEL, IMGN, ISEE, Jounce Therapeutics. NKTX, ORTX, RETA, SGEN, TSVT, QURE.
- Deep Track Capital was a net seller of stock by $-414M.
- Deep Track Capital has $2.2B in assets under management (AUM), dropping by -11.28%.
- Central Index Key (CIK): 0001856083
Tip: Access up to 7 years of quarterly data
Positions held by Deep Track Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Deep Track Capital
Deep Track Capital holds 55 positions in its portfolio as reported in the June 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 7.2 | $155M | +4% | 1.3M | 123.97 |
|
| Insmed Com Par $.01 (INSM) | 6.3 | $137M | 6.5M | 21.10 |
|
|
| Ionis Pharmaceuticals (IONS) | 5.4 | $116M | 2.8M | 41.03 |
|
|
| Travere Therapeutics (TVTX) | 5.2 | $113M | +19% | 7.4M | 15.36 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 5.1 | $110M | 2.6M | 41.57 |
|
|
| Immunovant (IMVT) | 4.8 | $103M | -27% | 5.4M | 18.97 |
|
| Intra Cellular Therapies (ITCI) | 4.5 | $98M | -8% | 1.5M | 63.32 |
|
| Alkermes SHS (ALKS) | 4.3 | $94M | 3.0M | 31.30 |
|
|
| Springworks Therapeutics (SWTX) | 4.3 | $93M | +14% | 3.5M | 26.22 |
|
| Dynavax Technologies Corp Com New (DVAX) | 3.9 | $85M | +3% | 6.6M | 12.92 |
|
| Geron Corporation (GERN) | 3.6 | $78M | -10% | 24M | 3.21 |
|
| Pliant Therapeutics (PLRX) | 3.4 | $73M | +18% | 4.1M | 18.12 |
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 3.3 | $72M | 2.8M | 25.52 |
|
|
| Verona Pharma Sponsored Ads (VRNA) | 3.1 | $67M | 3.2M | 21.14 |
|
|
| Guardant Health (GH) | 2.5 | $54M | NEW | 1.5M | 35.80 |
|
| 4d Molecular Therapeutics In (FDMT) | 2.3 | $50M | +21% | 2.8M | 18.07 |
|
| Agenus Com New (AGEN) | 2.2 | $48M | 30M | 1.60 |
|
|
| Beam Therapeutics (BEAM) | 1.9 | $42M | +5% | 1.3M | 31.93 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 1.7 | $36M | 15M | 2.38 |
|
|
| Intellia Therapeutics (NTLA) | 1.6 | $34M | +18% | 835k | 40.78 |
|
| Miragen Therapeutics (VRDN) | 1.4 | $30M | +4% | 1.3M | 23.79 |
|
| Nurix Therapeutics (NRIX) | 1.4 | $30M | 3.0M | 9.99 |
|
|
| Repare Therapeutics Ord (RPTX) | 1.3 | $29M | 2.7M | 10.58 |
|
|
| Editas Medicine (EDIT) | 1.3 | $28M | NEW | 3.5M | 8.23 |
|
| Dyne Therapeutics (DYN) | 1.3 | $28M | +7% | 2.5M | 11.25 |
|
| Biosante Pharmaceuticals (ANIP) | 1.3 | $28M | NEW | 514k | 53.83 |
|
| Axsome Therapeutics (AXSM) | 1.3 | $28M | NEW | 384k | 71.86 |
|
| Point Biopharma Global (PNT) | 1.2 | $25M | +18% | 2.8M | 9.06 |
|
| Edgewise Therapeutics (EWTX) | 1.0 | $21M | -10% | 2.8M | 7.75 |
|
| Zura Bio Class A Ord Shs (ZURA) | 1.0 | $21M | NEW | 2.5M | 8.20 |
|
| Pacific Biosciences of California (PACB) | 0.9 | $19M | -58% | 1.5M | 13.30 |
|
| Acumen Pharmaceuticals (ABOS) | 0.9 | $19M | 3.9M | 4.81 |
|
|
| Rapt Therapeutics (RAPT) | 0.9 | $19M | +75% | 1.0M | 18.70 |
|
| Prothena Corp SHS Put Option (PRTA) | 0.8 | $17M | NEW | 250k | 68.28 |
|
| Vigil Neuroscience (VIGL) | 0.8 | $17M | -12% | 1.8M | 9.40 |
|
| Astria Therapeutics (ATXS) | 0.7 | $14M | -6% | 1.7M | 8.33 |
|
| Nuvation Bio Com Cl A (NUVB) | 0.6 | $14M | 7.7M | 1.80 |
|
|
| Morphic Hldg (MORF) | 0.6 | $12M | NEW | 217k | 57.33 |
|
| Silence Therapeutics Ads (SLN) | 0.5 | $11M | 2.0M | 5.50 |
|
|
| Orchard Therapeutics Spon Ads New | 0.5 | $11M | NEW | 2.0M | 5.21 |
|
| Nektar Therapeutics (NKTR) | 0.5 | $10M | +931% | 18M | 0.58 |
|
| Terns Pharmaceuticals (TERN) | 0.4 | $9.6M | NEW | 1.1M | 8.75 |
|
| 89bio (ETNB) | 0.4 | $9.5M | -72% | 503k | 18.95 |
|
| Inozyme Pharma (INZY) | 0.4 | $9.2M | -49% | 1.6M | 5.57 |
|
| Zentalis Pharmaceuticals (ZNTL) | 0.4 | $8.5M | NEW | 300k | 28.21 |
|
| Relmada Therapeutics (RLMD) | 0.3 | $7.0M | 2.8M | 2.46 |
|
|
| Gh Research Ordinary Shares (GHRS) | 0.3 | $5.9M | 499k | 11.87 |
|
|
| Compass Pathways Sponsored Ads (CMPS) | 0.3 | $5.6M | NEW | 678k | 8.28 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.3 | $5.5M | NEW | 109k | 51.00 |
|
| Century Therapeutics (IPSC) | 0.1 | $3.2M | 1.0M | 3.16 |
|
|
| Heron Therapeutics (HRTX) | 0.1 | $2.4M | -35% | 2.1M | 1.16 |
|
| Fibrogen Call Option (FGEN) | 0.1 | $2.1M | NEW | 765k | 2.70 |
|
| Allakos (ALLK) | 0.0 | $995k | -93% | 228k | 4.36 |
|
| Immunic (IMUX) | 0.0 | $774k | -87% | 308k | 2.51 |
|
| Mink Therapeutics (INKT) | 0.0 | $682k | NEW | 325k | 2.10 |
|
Past Filings by Deep Track Capital
SEC 13F filings are viewable for Deep Track Capital going back to 2021
- Deep Track Capital 2023 Q2 restated filed Sept. 6, 2023
- Deep Track Capital 2023 Q2 filed Aug. 14, 2023
- Deep Track Capital 2023 Q1 filed May 15, 2023
- Deep Track Capital 2022 Q4 filed Feb. 14, 2023
- Deep Track Capital 2022 Q3 filed Nov. 14, 2022
- Deep Track Capital 2022 Q2 filed Aug. 12, 2022
- Deep Track Capital 2022 Q1 filed May 16, 2022
- Deep Track Capital 2021 Q4 filed Feb. 14, 2022